Clinical Trial Update: Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults. [Phase 1]

View source ↗

Summary

A Phase 1 study reports on the safety and immunogenicity of GlaxoSmithKline's TB vaccine candidate Mtb72F/AS02 in healthy PPD-negative adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Mtb72F/AS02

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tuberculosis (TB) | Phase 1 | Status: COMPLETED